Mitomics Announces U.S. Sales and Marketing Agreement with LabCorp
Urologists Able to Order Prostate Core Mitomic Test™ through LabCorp's DIANON Systems Laboratory
THUNDER BAY, ON, Oct. 10, 2012 /CNW/ - Mitomics, a world leader in the research and development of mitochondrial genome-based products, today announced an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a leading provider of medical laboratory tests and services. Under the agreement, urologists will be able to order Mitomics' flagship laboratory test, the Prostate Core Mitomic Test™ (PCMT), through DIANON Systems, Inc., a specialized laboratory subsidiary of LabCorp focusing on anatomic pathology, including uropathology. The PCMT was developed by Mitomics and will be performed at Mitomics CLIA laboratory in Aurora, Colorado.
"We are pleased to partner with LabCorp and DIANON to offer convenient ordering of and information about PCMT to their urology customers throughout the U.S.," said Robert Poulter, president and chief executive officer of Mitomics. "This agreement supports our commercial strategy to provide broad access to PCMT and further validates the strong demand from physicians to improve the diagnosis of prostate cancer for patients."
About the Prostate Core Mitomic Test™ (PCMT)
PCMT is a highly advanced, patented test based on the science of mitochondrial DNA (mtDNA). Using previously obtained prostate biopsy tissue, PCMT can determine the presence of malignant cells via a cancerization field effect by detecting underlying molecular alterations in normal-appearing tissue. This is all performed quickly and easily with a simple lab test. For more information or to order PCMT, please visit the PCMT web page.
Mitomics is the world leader in the research and development of mitochondrial DNA (mtDNA)-based biomarkers - a new and innovative approach to the detection of cancer and other disease states. Leveraging its unparalleled insights into the role of mitochondria in cancer, the company is developing an extensive and proprietary portfolio of molecular tests that address significant unmet needs in oncology and gynecology, including those for the early detection of prostate and breast cancer, as well as a test for endometriosis. Mitomics currently markets the Prostate Core Mitomic Test™, a highly accurate laboratory developed test for detecting the absence or presence of cancerous cells using existing prostate biopsy tissue, and plans to launch several additional breakthrough molecular tests based on its Mitomic Technology™ in the coming years. The company is headquartered in Thunder Bay, Ontario, Canada and operates a CLIA compliant clinical laboratory in Aurora, Colorado. For more information, please visit www.mitomicsinc.com.
SOURCE: Mitomics Inc.For further information:
Manager, Media Relations